ECG

Romance isn’t always rosy, sometimes it’s sickening – lovesickness, erotomania and death by heartbreak explained

Retrieved on: 
Tuesday, February 13, 2024
Well, Affection, Love, Fantasy, Takotsubo cardiomyopathy, Architecture, Perspiration, Palpitations, MacEwen, News, Heart, Dizziness, Basilica, Nausea, ECG, Erotomania, Vomiting, Myocardial infarction, Syndrome, Health, Delusion, City, Florentine, Death, DSM-IV codes, Disease, Hallucination, Research, Human, Beauty, Brain

All you need is love.

Key Points: 
  • All you need is love.
  • It’s better to have loved and lost than never to have loved at all.
  • But is love all pink hearts, roses and teddy bears – or is there a darker side?

Pathological Love

  • Love can hurt.
  • Ian McEwan framed a pathological form of affection, leading to obsession in his 1997 novel “Enduring Love”.
  • They appear even in the words of Hippocrates, described as a form of unrequited love.
  • The condition has seen a renaissance, over the past three centuries, shifting from unanswered love to sex addiction, to its current standing of delusions of love.

I love Paris in the springtime

  • Love, or perceptions of love for material objects or places rather than individuals might also be enough to trigger psychiatric illness.
  • Stendhal was not a psychiatrist, but a writer, who found himself overcome by the beauty of Florence when travelling there in 1817.
  • For others, unfortunately not – leading to a condition known as Paris Syndrome.

Too many broken hearts in the world

  • The term broken heart syndrome applies to a genuine cardiac condition – Takotsubo cardiomyopathy.
  • The underlying cause of broken heart syndrome?
  • The raised levels of adrenaline have been proposed as an underlying cause of broken heart syndrome – a link between heart and mind – though more research is required to tell for sure.


Dan Baumgardt does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

HeartSciences Expands its Scientific Advisory Board

Retrieved on: 
Monday, February 12, 2024
Bangladesh Technical Education Board, Accreditation, HSCS, American Society of Echocardiography, Algorithm, Research, American Heart Association, Artificial intelligence, AI, Intelligence, Assistant, FDA, Outcomes research, Diagnostic medical sonography, ECG, Education, Society, GE HealthCare, American College, Journal, Machine learning, Harvard Medical School, ACC, Commission, Medical device

Southlake, TX, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Jordan B. Strom M.D., M.Sc., to its Scientific Advisory Board.

Key Points: 
  • Southlake, TX, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Jordan B. Strom M.D., M.Sc., to its Scientific Advisory Board.
  • Strom has been assisting us in recent interactions with the FDA and we are delighted to welcome him to our Scientific Advisory Board as we prepare for FDA submission of our MyoVista device and cloud platform, in addition to algorithms licensed from the Icahn School of Medicine at Mount Sinai, New York.
  • Dr. Strom has expertise in AI-based medical devices and is a consultant to GE Healthcare, Phillips Healthcare, and Edwards Life Sciences.
  • HeartSciences is an innovator in this field, and I look forward to helping them unleash the potential power of AI-powered ECGs to help clinicians deliver timely and optimal care.

Prenetics Announces MOU for a Strategic Investment and 5-Year Research Collaboration with Metavisionaries to Pioneer R&D on the International Space Station

Retrieved on: 
Friday, February 9, 2024
MOU, University, University of Oxford, Partnership, Associate, MRI, CAT, ECG, Health, Rejuvenation, SpaceX, Ageing, Research, Longevity, Space research, NASA, ISS

DUBAI, United Arab Emirates, Feb. 09, 2024 (GLOBE NEWSWIRE) -- UAE Space Agency – Prenetics Global Limited (NASDAQ:PRE), a leading genomics-driven health sciences company, announces the signing of a Memorandum of Understanding (MOU), that paves the way for a strategic investment in Metavisionaries and a pioneering five-year research agreement with them and their partners Space Application Services through their Metaspace Venture. The parties will also establish a Space Innovation Lab within the UAE Space Agency. The inaugural Prenetics research cube is scheduled to on-board the SpaceX to the ISS in Q4 of 2024.

Key Points: 
  • The parties will also establish a Space Innovation Lab within the UAE Space Agency.
  • The inaugural Prenetics research cube is scheduled to on-board the SpaceX to the ISS in Q4 of 2024.
  • Concurrently, Danny Yeung, CEO of Prenetics will join the Board of Directors at Metavisionaries, fortifying its strategic vision.
  • I’m excited to contribute to Prenetics' mission and to translate space research into health innovations on Earth,” said Dr. James L. Green.

IRHYTHM ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against iRhythm Technologies, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, February 8, 2024
Atrial fibrillation, Growth, Telephone, IRTC, Patient, P.C, FDA, Marketing, Justice, Boston Scientific, ECG, DOJ, District court, Zio, Heart failure, J. P. Morgan, Stroke, Subpoena duces tecum, Court, Person, Medical device

Investors have until April 8, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until April 8, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • iRhythm develops and manufactures heart monitoring devices designed to diagnose arrythmias.
  • The Company’s principal product is a monitoring patch that provides electrocardiogram (“ECG”) monitoring for up to 14 days, called Zio XT.
  • As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices throughout the Class Period.

Sibel Announces its 4th FDA Clearance for Continuous Wearable Vital Signs Monitoring with ANNE® One and Additional Strategic Collaboration with Ann & Robert H. Lurie Children's Hospital of Chicago

Retrieved on: 
Wednesday, February 7, 2024
Continuity, Research institute, Hospital, Research, Patient, Adolescence, Temperature, Lurie Children's Hospital, FDA, Vital signs, ECG, Entrepreneurship, Food, Health, Premature, Disability, Assistant, Neurology, Feinberg School of Medicine, Oxygen saturation (medicine), IZotope, Pleasure, Digital health, Nursing

CHICAGO, Feb. 7, 2024 /PRNewswire/ -- Sibel Health, a leading digital health company, announced today that its continuous wearable monitoring solution, ANNE® One, has received another 510(k) clearance from the U.S. Food and Drug Administration (FDA). The ANNE® One platform now allows for continuous ambulatory ECG monitoring, SpO2, temperature, and non-invasive blood pressure measurements. In addition, this new clearance extends the population to include individuals 12 years and above for monitoring in the home and hospital settings.

Key Points: 
  • The ANNE® One platform now allows for continuous ambulatory ECG monitoring, SpO2, temperature, and non-invasive blood pressure measurements.
  • In addition, this new clearance extends the population to include individuals 12 years and above for monitoring in the home and hospital settings.
  • Steve Xu MD, Co-Founder and CEO of Sibel Health, said "Our mission here at Sibel Health is to deliver Better Health Data for All®.
  • Sibel Health also announces a new collaboration with Ann & Robert H. Lurie Children's Hospital of Chicago and its research enterprise, Stanley Manne Children's Research Institute.

Shareholder Alert: Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against iRhythm Technologies, Inc.

Retrieved on: 
Wednesday, February 7, 2024
Class Action Lawsuit, Professional Services, Legal, Pension, Atrial fibrillation, Class, Growth, BLB, Patient, Complaint, FDA, Marketing, Justice, Boston Scientific, ECG, DOJ, District court, Action Replay, Zio, Heart failure, J. P. Morgan, Stroke, Subpoena duces tecum, Court, Person, Medical device

The action is brought on behalf of all persons or entities that purchased or otherwise acquired iRhythm common stock between January 11, 2022, and May 30, 2023, inclusive (the “Class Period”).

Key Points: 
  • The action is brought on behalf of all persons or entities that purchased or otherwise acquired iRhythm common stock between January 11, 2022, and May 30, 2023, inclusive (the “Class Period”).
  • The complaint is based on an extensive investigation and a careful evaluation of the merits of this case.
  • The Company’s principal product is a monitoring patch that provides electrocardiogram (“ECG”) monitoring for up to 14 days, called Zio XT.
  • As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices throughout the Class Period.

EQS-News: TVM CAPITAL LIFE SCIENCE CO-LEADS $16 MILLION SERIES A FINANCING ROUND FOR VEKTOR MEDICAL TO REVOLUTIONIZE ARRHYTHMIA CARE

Retrieved on: 
Tuesday, February 6, 2024
Atrial fibrillation, Vektor, Extended play, Patient, FDA, Investment, ECG, Arrhythmia, Physician, General partnership, Vector, TVM

Munich, Germany and Montreal, Quebec, Canada, February 6, 2024 – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced a $16 million Series A financing for Vektor Medical, a pioneer in non-invasive, AI-based arrhythmia analysis technology.

Key Points: 
  • Munich, Germany and Montreal, Quebec, Canada, February 6, 2024 – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced a $16 million Series A financing for Vektor Medical, a pioneer in non-invasive, AI-based arrhythmia analysis technology.
  • The proceeds will be used to support the commercialization of vMap®, Vektor’s AI-based arrhythmia analysis tool, which is transforming how electrophysiologists (EPs) approach ablation procedures.
  • Dr. Luc Marengère, Managing Partner at TVM, will join the Vektor Medical Board of Directors, and Dr. Sascha Berger, General Partner at TVM, will serve as a Board Observer.
  • Dr. Luc Marengère, Managing Partner at TVM Capital Life Science, said: “Changing the standard of care demands a unique and transformative approach.

TVM Capital Life Science Co-Leads $16 Million Series A Financing Round for Vektor Medical to Revolutionize Arrhythmia Care

Retrieved on: 
Tuesday, February 6, 2024
Atrial fibrillation, Vektor, Extended play, Patient, FDA, Investment, ECG, Arrhythmia, Physician, General partnership, Vector, TVM

MUNICH, Germany and MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced a $16 million Series A financing for Vektor Medical, a pioneer in non-invasive, AI-based arrhythmia analysis technology.

Key Points: 
  • MUNICH, Germany and MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced a $16 million Series A financing for Vektor Medical, a pioneer in non-invasive, AI-based arrhythmia analysis technology.
  • Dr. Luc Marengère, Managing Partner at TVM, will join the Vektor Medical Board of Directors, and Dr. Sascha Berger, General Partner at TVM, will serve as a Board Observer.
  • Vektor’s vMap is the only FDA-cleared, non-invasive AI-based solution for arrhythmia localization and analysis, seamlessly leveraging only a 12-lead ECG.
  • Dr. Luc Marengère, Managing Partner at TVM Capital Life Science, said: “Changing the standard of care demands a unique and transformative approach.

Vektor Medical Secures $16 Million Series A Funding

Retrieved on: 
Monday, February 5, 2024
Health, Medical Devices, Hospitals, Health Technology, General Health, Cardiology, Biotechnology, TVM, Vektor, Extended play, Patient, FDA, Medicine, ECG, Arrhythmia, Physician, Vector, Atrial fibrillation

Vektor Medical , a pioneer in non-invasive, AI-based arrhythmia analysis technology, today announced a $16 million Series A investment co-led by Solas BioVentures and TVM Capital Life Science.

Key Points: 
  • Vektor Medical , a pioneer in non-invasive, AI-based arrhythmia analysis technology, today announced a $16 million Series A investment co-led by Solas BioVentures and TVM Capital Life Science.
  • This funding underscores investor confidence in Vektor’s vision and ability to successfully execute its mission to revolutionize arrhythmia care.
  • “The medical community is being confronted with the necessity for change.
  • With an increasing atrial fibrillation (AF) patient population, outcomes must be improved while also enhancing procedure efficiency,” said Rob Krummen, CEO of Vektor Medical.

HeartSciences Appoints New Scientific Advisory Board Member

Retrieved on: 
Thursday, February 1, 2024
Intelligence, Genetics, University, Cardiovascular disease, Machine learning, Diagnosis, FDA, Drug discovery, ECG, Doctor of Philosophy, Health, HSCS, Assistant, Patent, Algorithm, Data science, Medical device

Southlake, TX, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Benjamin Glicksberg, Ph.D. to its Scientific Advisory Board.

Key Points: 
  • Southlake, TX, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Benjamin Glicksberg, Ph.D. to its Scientific Advisory Board.
  • “We are delighted to welcome Dr. Glicksberg, an elite data scientist and an instrumental leader in the establishment of the AI-ECG program at the Icahn School of Medicine at Mount Sinai, New York (Mount Sinai) to HeartSciences’ Scientific Advisory Board,” said Andrew Simpson, CEO of HeartSciences.
  • As part of this process, we are actively expanding our Scientific Advisory Board to include industry experts and broaden our outreach.
  • I am impressed by their proven track record of innovation and look forward to contributing to HeartSciences at the forefront of this field.”